Stock Events

Stock Events

Forum Markets 

€2.42
0
+€0.02+0.83% Wednesday 06:15

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

3JunExpected
Q4 2023
Next
Next
-210.38
-210.05
-209.72
-209.38
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow L270.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
CRISPR Therapeutics is involved in gene editing, a cutting-edge area of biotechnology that could compete with 180 Life Sciences' novel therapeutic approaches.
Editas Medicine
EDIT
Mkt Cap261.32M
Editas Medicine operates in the genome editing space, directly competing with 180 Life Sciences in developing treatments for diseases with unmet medical needs.
Intellia Therapeutics
NTLA
Mkt Cap1.55B
Intellia Therapeutics is another key player in the CRISPR/Cas9 technology sector, potentially competing with 180 Life Sciences in the field of genetic and autoimmune diseases.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals focuses on creating transformative medicines for people with serious diseases, which aligns with 180 Life Sciences' mission, making them competitors.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals is known for its innovation in biotechnology, competing with 180 Life Sciences in developing novel therapeutics for various diseases.
Alnylam Pharmaceuticals
ALNY
Mkt Cap42.29B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, competing with 180 Life Sciences in the development of novel treatments for genetic and other diseases.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.67B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and other innovative treatments for rare genetic diseases, competing with 180 Life Sciences in the rare disease space.
Sarepta Therapeutics
SRPT
Mkt Cap2.44B
Sarepta Therapeutics is focused on the discovery and development of RNA-based therapeutics, competing with 180 Life Sciences in the development of innovative treatments for diseases.

About

ETHZilla operates in digital asset management, gaming, and entertainment. The Company is developing an Ether (ETH) accumulation vehicle to serve as a benchmark for on-chain treasury management among public companies, supported by Electric Capital and a DeFi Council of industry experts. Its strategy targets yield generation beyond traditional ETH staking while advancing gaming initiatives and pursuing monetization of legacy biotechnology assets from its origins as a biotech company.
Show more...
CEO
Mr. McAndrew Rudisill BA(Econ)
Employees
4
Country
US
ISIN
US68236V4014
WKN
000A41M8H

Listings

F
DE
L270.F
BOATS
BOATS
ETHZ.BOATS
XNAS
US
FRMM

0 Comments

Share your thoughts

FAQ

What is Forum Markets stock price today?▼
The current price of L270.F is €2.42 EUR — it has increased by +0.83% in the past 24 hours. Watch Forum Markets stock price performance more closely on the chart.
What is Forum Markets stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Forum Markets stocks are traded under the ticker L270.F.
When is the next Forum Markets earnings date?▼
Forum Markets is going to release the next earnings report on June 03, 2026.
How many employees does Forum Markets have?▼
As of April 06, 2026, the company has 4 employees.
When did Forum Markets complete a stock split?▼
Forum Markets has not had any recent stock splits.
Where is Forum Markets headquartered?▼
Forum Markets is headquartered in Palm Beach, US.